Skip to content

AngioDynamics ANGO Proceeds from secured term loan

Proceeds from secured term loan at other companies

Haemonetics logo
HaemoneticsHAE
$0-100%
IAR
Integra LifeSciencesIART
$44.5M-18.2%

Other financials

Income statement

See full
Revenue$78.4M+8.9%
Gross profit$41.5M+6.7%
Operating income-$13.0M-29.8%
Net income-$8.1M-83.4%
EPS (diluted)-$0.19-72.7%

Balance sheet

See full
Cash & equivalents$37.8M-15.5%
Total debt$7.9M+10.2%
Total equity$173.4M-6.7%
Total assets$260.7M-8.7%

Cash flow

See full
Operating cash flow-$3.1M+76.4%
CapEx$1.0M-43.5%
Free cash flow-$4.1M+72.4%

Valuation

See full
Market cap$564.42M+38.7%
Enterprise value$534.51M+48.0%
P/S1.8×+0.4×

Profitability

See full
Gross margin54.3%-0.1pp
Operating margin-11.3%-2.9pp
Net margin-10%-2.4pp
FCF margin5.5%

Returns & leverage

See full
Return on equity-17.5%-2.2pp
Debt / equity0.0×
Current ratio2.4×+0.1×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSecuredDebt.

The official record: AngioDynamics’s 10-K, filed July 18, 2025, on SEC EDGAR. View the filing →

Ask your AI about AngioDynamics's proceeds from secured term loan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AngioDynamics's proceeds from secured term loan?
AngioDynamics (ANGO) reported proceeds from secured term loan of $1.58M in Q1 2025.
What does proceeds from secured term loan mean?
This represents the cash inflows received from borrowing against collateralized assets or specific debt facilities. It indicates the company's ability to access credit markets to fund operations, acquisitions, or capital expenditures. Monitoring this helps assess the company's leverage profile and its reliance on external financing.